Biognosys and Biodesix work together

Biognosys, a leader in next-generation proteomics, has announced that US company Biodesix will begin offering Biognosys’ HRM technology as part of its companion diagnostic development capabilities to develop novel protein assays for the cancer market. The collaboration will give Biognosys access to advanced mass spectrometric technology.

Biodesix is a molecular diagnostics company that commercialises blood-based diagnostic tests for precision medicine in cancer. It is expanding its collaborations with pharmaceutical and biotech companies to bring new blood-based tests to market. The inclusion of Biognosys’ technology will offer new ways to discover biomarkers with Biodesix’ analytical platform. Compared with other mass spectrometry labelling approaches, the sample preparation is much simpler and there are no limitations on the number of samples that can be analysed.

Schlieren-based Biognosys was founded in 2008 as an ETH Zurich spin-off. It is a pioneer in the field of proteomics in the pharma, biotech, diagnostics and agricultural industries, and offers services and products for precise high-content protein quantification. It believes that the decoding of the proteome will affect life sciences more than the genome revolution a decade ago.